Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. (symbol: CTNM) is a cutting-edge clinical stage biopharmaceutical company dedicated to the discovery and development of novel, oral small molecule therapies targeting neuroinflammation and immunology (NI&I) indications with high unmet medical needs. The company's core business revolves around its internally-developed drug candidates, notably PIPE-791 and PIPE-307.
PIPE-791 is a groundbreaking, brain-penetrant small molecule inhibitor of the LPA1R receptor. This innovative drug is currently in development for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a severe lung disease with limited effective treatments. PIPE-307, on the other hand, is a selective inhibitor of the muscarinic type 1 receptor (M1R). This potential therapy is being developed to address depression and Relapsing-Remitting Multiple Sclerosis (RRMS). These drug candidates highlight Contineum Therapeutics' commitment to addressing significant areas of unmet need in the medical field.
The company has seen recent achievements in both preclinical and early clinical trials, showcasing promising results that underline the potential efficacy and safety of their drug candidates. Contineum Therapeutics is actively involved in multiple ongoing projects and collaborations aimed at accelerating the development and commercialization of their innovative therapies.
Financially, Contineum Therapeutics continues to secure funding to support its research and development activities, ensuring robust pipelines and sustained operational capabilities. The company's strategic partnerships and collaborations with key stakeholders in the biopharmaceutical industry further bolster its position as a leader in the NI&I therapeutic space.
For investors and stakeholders, Contineum Therapeutics represents a unique opportunity in the biopharmaceutical sector, driven by its innovative approach, solid financial health, and a clear focus on addressing critical medical needs.
Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in its Phase 1b PET trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting the LPA1 receptor. The open-label, single-center trial aims to evaluate receptor occupancy in the brain and lungs of multiple patient cohorts, including healthy volunteers, idiopathic pulmonary fibrosis (IPF), and progressive multiple sclerosis (PrMS) patients.
The study will measure the correlation between pharmacokinetics and receptor occupancy using PET imaging. The company expects to release topline data in the second quarter of 2025. The trial is registered under NCT06683612.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on December 4, 2024, at 11:15 a.m. ET in Miami. The event will be accessible via audio webcast through Contineum's website's Investors section, with a replay option available.
Contineum Therapeutics (NASDAQ: CTNM) received FDA authorization for its IND application for PIPE-791, targeting chronic pain treatment. The company plans to commence a Phase 1b study in Q1 2025 for osteoarthritis and low back pain treatment. The study will be randomized, double-blind, placebo-controlled, involving approximately 40 patients across five sites with a 28-day treatment duration. Topline data is expected in early 2026. PIPE-791 is a novel brain penetrant small molecule antagonist of LPA1R, targeting neuropathic pain components. The company's cash position of $213.9 million is expected to fund operations through 2027.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in two major investor conferences in November 2024.
The company will attend the Stifel 2024 Healthcare Conference in New York on November 18, where CEO Carmine Stengone will present at 4:10 p.m. ET. Additionally, management will participate in one-on-one meetings at the Jefferies 2024 London Healthcare Conference on November 21. The Stifel presentation will be available via webcast on Contineum's website with replay access.
Contineum Therapeutics (Nasdaq: CTNM) reported its Q3 2024 financial results and recent business highlights. The company continued enrolling patients in its Phase 2 VISTA trial of PIPE-307 for RRMS, achieving two-thirds enrollment. It expects full enrollment by H1 2025. Contineum submitted a CTA to the MHRA for a Phase 1b trial of PIPE-791, targeting healthy volunteers and patients with progressive multiple sclerosis and IPF, aiming to start in December 2024. Janssen Pharmaceutica remains on track to start a Phase 2 trial of PIPE-307 in depression. The company holds $214 million in cash, expected to support operations through 2027. Q3 R&D expenses rose to $9.7 million from $6.5 million YoY, driven by increased costs for ongoing trials and toxicology studies. General and administrative expenses also increased to $3.3 million from $1.6 million YoY, mainly due to higher stock-based compensation and consulting costs.
Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications, will be represented by its President and CEO, Carmine Stengone.
The conferences are:
- Morgan Stanley 22nd Annual Global Healthcare Conference (September 4-6, 2024, New York) - Presentation on September 4 at 7:00 am ET
- H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024, New York) - Presentation on September 10 at 2:30 pm ET
Both presentations will be available via webcast on Contineum's website, with replays accessible after the events conclude.
Contineum Therapeutics (Nasdaq: CTNM) reported Q2 2024 financial results and recent business highlights. Key points include:
- Strong cash position of $219 million at Q2 end
- Appointed Troy Ignelzi and Sarah Boyce to Board of Directors
- Strengthened management team with John Healy and Kristina Haeckl
- Enrollment on track for PIPE-307 Phase 2 VISTA trial in RRMS
- Published preclinical and clinical results on PIPE-307 and PIPE-791
- Completed IPO with net proceeds of $107.9 million
Financial results:
- R&D expenses: $7.9 million (Q2 2024) vs $9.5 million (Q2 2023)
- G&A expenses: $3.0 million (Q2 2024) vs $1.6 million (Q2 2023)
Contineum Therapeutics (Nasdaq: CTNM) has announced the publication of encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist for relapse-remitting multiple sclerosis (RRMS), in the Proceedings of the National Academy of Science. The data suggest that PIPE-307 is a novel, selective inhibitor of the muscarinic type 1 M1 receptor, which may promote remyelination in multiple sclerosis.
The company has completed two Phase 1 trials in healthy volunteers and initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled proof-of-concept clinical trial (VISTA) in RRMS patients. This trial will assess efficacy and safety, measuring multiple clinical and imaging endpoints sensitive to changes in remyelination. PIPE-307 is being developed under a global license and development agreement with Janssen Pharmaceutica NV.
Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced its participation in the 45th Annual Goldman Sachs Healthcare Conference, from June 10-13, 2024, in Miami.
Carmine Stengone, President and CEO, will engage in a fireside chat on June 10 at 8:40 am ET, with the event webcast live on Contineum’s website. The company will also hold one-on-one meetings with investors throughout the conference.
Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced the appointment of John Healy as General Counsel & Corporate Secretary. Healy brings over 20 years of legal experience in the life sciences industry, including roles at Tyra Biosciences where he oversaw the company's IPO. He has also provided legal consulting to numerous biotech firms. CEO Carmine Stengone praised Healy's extensive experience and potential to guide Contineum through its growth. Healy expressed enthusiasm about joining Contineum and contributing to its advancement in neuroscience, inflammation, and immunology therapies.
FAQ
What is the current stock price of Contineum Therapeutics (CTNM)?
What is the market cap of Contineum Therapeutics (CTNM)?
What is Contineum Therapeutics, Inc.?
What are PIPE-791 and PIPE-307?
What are the areas of focus for Contineum Therapeutics?
What recent achievements has the company made?
How does Contineum Therapeutics support its research and development?
What opportunities does Contineum Therapeutics offer to investors?
What is the significance of PIPE-791?
What medical needs does PIPE-307 address?
What is the financial condition of Contineum Therapeutics?
What makes Contineum Therapeutics a leader in NI&I therapeutics?
